Category: Psychedelic Bulletin - Page 11 - Psychedelic Alpha

Read more about the article Psychedelic Bulletin: The Cost-Effectiveness of MDMA for PTSD; The Challenges Ahead for Psychedelic Medicine

Psychedelic Bulletin: The Cost-Effectiveness of MDMA for PTSD; The Challenges Ahead for Psychedelic Medicine

Post published:March 7, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Following the Money – How Much do Psychedelics Companies Spend on R&D?

Psychedelic Bulletin: Following the Money – How Much do Psychedelics Companies Spend on R&D?

Post published:February 28, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Tracking LSD Patents; Psilocybin Effective for a Year in Depression; Cybin Partners with Chopra Foundation

Psychedelic Bulletin: Tracking LSD Patents; Psilocybin Effective for a Year in Depression; Cybin Partners with Chopra Foundation

Post published:February 18, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Mindstate Design Labs Leaves Stealth Mode; No Synthetic Psilocybin in Oregon?

Psychedelic Bulletin: Mindstate Design Labs Leaves Stealth Mode; No Synthetic Psilocybin in Oregon?

Post published:February 14, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Patent Granted Covering DMT Vapes; Microdosing Produces “Negligible” Effects

Psychedelic Bulletin: Patent Granted Covering DMT Vapes; Microdosing Produces “Negligible” Effects

Post published:February 6, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: MDMA Fast-Tracked in UK; FDA Clears MindMed LSD Trial; More Psychedelic Drug Policy Reform Efforts Emerge

Psychedelic Bulletin: MDMA Fast-Tracked in UK; FDA Clears MindMed LSD Trial; More Psychedelic Drug Policy Reform Efforts Emerge

Post published:January 28, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: DEA Moves to Schedule 5 Tryptamines; Eleusis Unveils SPAC; COMPASS Seeks LSD Patents

Psychedelic Bulletin: DEA Moves to Schedule 5 Tryptamines; Eleusis Unveils SPAC; COMPASS Seeks LSD Patents

Post published:January 22, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: MindMed Co-Founder Resigns from Board; Global Coalition to Reschedule Psilocybin Emerges; We Review Psychedelic Research and Trials from 2021

Psychedelic Bulletin: MindMed Co-Founder Resigns from Board; Global Coalition to Reschedule Psilocybin Emerges; We Review Psychedelic Research and Trials from 2021

Post published:January 14, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Big Pharma’s Foray Into Psychedelics; Psilocybin Trial Makes Headlines; Bill to Legalize Psilocybin in Washington State Filed

Psychedelic Bulletin: Big Pharma’s Foray Into Psychedelics; Psilocybin Trial Makes Headlines; Bill to Legalize Psilocybin in Washington State Filed

Post published:January 7, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: First Look at Field Trip’s FT-104 Molecule; MindMed Trial Halted by FDA, Changes at the Top

Psychedelic Bulletin: First Look at Field Trip’s FT-104 Molecule; MindMed Trial Halted by FDA, Changes at the Top

Post published:December 31, 2021
Post category:Psychedelic Bulletin

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.